The domestic pharma and biotech industry is speeding up the development of new antibody-drug conjugates (ADCs), unveiling their clinical results. At the 'World ADC 2024' that was held in San Diego, U.S. for 4 days from the 4th of this month, domestic pharmaceutical bio companies including Celltrion, LigaChem Biosciences, and ABL Bio revealed ADC research results. With the results, the companies are aiming to secure various solid cancer indications such as non-small cell lung cancer, bladder cancer, and breast cancer.

Celltrion seeks to develop a new ADC drug with the Pinotbio platform


According to industry sources on the 9th, Celltrion unveiled the preclinical results of its AD